{
    "clinical_study": {
        "@rank": "33469", 
        "acronym": "MOTION - JAPAN", 
        "arm_group": [
            {
                "arm_group_label": "Part A Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Part A Placebo orally twice daily"
            }, 
            {
                "arm_group_label": "Part A fampridine (BIIB041)", 
                "arm_group_type": "Experimental", 
                "description": "Part A fampridine (BIIB041) 10mg orally twice daily"
            }, 
            {
                "arm_group_label": "Part B fampridine (BIIB041)", 
                "arm_group_type": "Experimental", 
                "description": "Part B fampridine (BIIB041) 10mg orally twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter study conducted in 2 parts. Part A is a double-blind\n      placebo-controlled parallel-group period, and Part B is an open-label extension period. The\n      primary objective of the double-blind study (Part A) is to assess the effect of\n      Prolonged-Release Fampridine, treatment on walking speed, in Japanese patients with Multiple\n      Sclerosis. The secondary objectives of the double-blind portion of the study are to evaluate\n      the safety and tolerability of prolonged-release Fampridine in this study population. The\n      primary endpoint of the open-label extension study (Part B) is to evaluate the long-term\n      safety profile of prolonged-release Fampridine."
        }, 
        "brief_title": "A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Sclerosis, Remittent Progressive", 
            "Multiple Sclerosis, Primary Progressive", 
            "Relapsing-Remitting Multiple Sclerosis", 
            "Secondary Progressive Multiple Sclerosis", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Chronic Progressive", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Part A\n\n        To be eligible to participate in Part A, candidates must meet the following eligibility\n        criteria at screening or at the timepoint specified in the individual eligibility\n        criterion listed (potential subjects who fail screening may be rescreened 1 time):\n\n          1. Must have a diagnosis of primary-progressive, secondary progressive, progressive\n             relapsing, or relapsing-remitting MS as defined by the revised McDonald Committee\n             criteria ([Lublin and Reingold 1996; McDonald 2001; Polman 2005]) of at least 2\n             months duration.\n\n          2. Must be able to complete the T25FW with or without a walking aid in an average of 8\n             to 45 seconds at the screening visit.\n\n        Part B\n\n        To be eligible to participate in Part B, candidates must meet the following criteria at\n        the Week 21 visit in Part A, which is the first visit for Part B:\n\n        1. Completed all visits in Part A of the study.\n\n        Exclusion Criteria:\n\n          1. Known allergy to pyridine-containing substances, or any of the inactive ingredients\n             of the prolonged-release fampridine tablet\n\n          2. Any prior history of seizures, epilepsy, or other convulsive disorder, with the\n             exception of febrile seizures in childhood, or prior history of epileptiform activity\n             on electroencephalogram.\n\n          3. Any form of renal impairment as defined by a creatinine clearance (CrCl) of <80\n             mL/min (estimated by the central laboratory).\n\n          4. Known history of cardiac arrhythmia or cardiac conduction disorders requiring medical\n             or surgical intervention, or any clinically significant ECG abnormality (as\n             determined by the Investigator) at the screening visit or Day 1.\n\n          5. Any prior treatment with fampridine (4 AP) or 3,4 diaminopyridine in any formulation.\n\n          6. Treatment with an investigational drug or approved therapy for investigational use\n             within 30 days (or 5 half lives, whichever is longer) prior to the screening visit.\n\n          7. Participation in an investigational study (with the exception of observational\n             studies) within 30 days prior to the screening visit or plans to enroll in another\n             interventional investigational study at any time during this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "128", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917019", 
            "org_study_id": "218MS304"
        }, 
        "intervention": [
            {
                "arm_group_label": "Part A Placebo", 
                "description": "Placebo orally twice daily", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Part A fampridine (BIIB041)", 
                    "Part B fampridine (BIIB041)"
                ], 
                "description": "fampridine (BIIB041) 10mg orally twice daily", 
                "intervention_name": "fampridine (BIIB041)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "4-Aminopyridine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Japan", 
        "lastchanged_date": "November 1, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fuchu", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morioka", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niigata", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-Shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension", 
        "overall_contact": {
            "email": "neurologyclinicaltrials@biogenidec.com", 
            "last_name": "Biogen Idec"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency (PMDA)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The proportion of subjects who show a consistent improvement in walking speed", 
                "safety_issue": "No", 
                "time_frame": "Part A (Up to 21 Weeks)"
            }, 
            {
                "measure": "Numer of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Part B (54 Weeks)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of patients with Adverse Events (AEs) and Serious Adverse Events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Part A (Up to 21 Weeks)"
        }, 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}